Corcept Therapeutics Incorporated Financials

Market Capitalization $7.66 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	62.84
Forward PE	41.30
Price to Sales TTM	$11.18
Price to Book MRQ	$11.21
Enterprise to Revenue	10.90
Enterprise to EBITDA	67.08

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	19.55%
Operating Margin	2.17%
Return on Assets TTM	9.18%
Return on Equity TTM	21.77%

Income Statement

Revenue TTM	$685,446,016
Revenue per Share TTM	$6.62
Quarterly Revenue Growth	7.10%
Gross Profit TTM	$674,195,968
EBITDA	$112,487,000
Net Income to Common TTM	$132,507,000
Diluted EPS TTM	$1.15
Quarterly Earnings Growth YoY	-26.00%

Balance Sheet

Total Cash MRQ	$322,763,008
Total Cash per Share MRQ	$3.04
Total Debt MRQ	$
Total Debt to Equity MRQ	1.00
Current Ratio MRQ	3.07
Book Value per Share MRQ	$6.45

Cash Flow

Operating Cash Flow TTM	$179,439,008
Levered Free Cash Flow TTM	$160,079,376

CORT Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	105,113,000
Float Shares	87,673,513
Avg 10 Volume	2,130,490
Avg 30 Volume	None
Shares Short	12,652,014
Short Ratio	9.21
Short % of Shares	16.08%
% Held by Insiders	11.49%
% Held by Institutions	79.64%

Stock Price Summary

Beta	0.18
Fifty Two Week Low	$29.42
Fifty Two Week High	$117.33
Fifty Two Week Change	58.38%
Day 50 MA	$72.65
Day 200 MA	$60.90

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date